Uncategorized

Lysogene Announces Filing of 2021 Universal Registration Document

Lysogene Announces Filing of 2021 Universal Registration Document 150 150 Lysogene

Paris, France — 20 April 2022 at 08:00 am — Lysogene (FR0013233475 – LYS), a…

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations

Lysogene Enters into an Exclusive Worldwide License Agreement with Yeda, the commercial arm of the Weizmann Institute of Science, for a Novel Gene Therapy Candidate for Neuronopathic Gaucher Disease and Parkinson Disease with GBA1 Mutations 150 150 Lysogene

Lysogene exercises its option after a conclusive research collaboration period Paris, France — 12 April 2022…

Lysogene Reports Full Year 2021 Financial Results

Lysogene Reports Full Year 2021 Financial Results 150 150 Lysogene

Paris, France – 31 March 2022 at 8:00 am CET – Lysogene (FR0013233475 – LYS),…

Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022

Lysogene Reports Additional Positive Biomarker data with LYS-SAF302 and Favorable Safety data with LYS-GM101 presented at the WORLDSymposium™ 2022 150 150 Lysogene

New positive biomarker data from 16 patients treated with LYS-SAF302 showing reduction in heparan sulfate…

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome

Lysogene Enters into an Exclusive Worldwide License Agreement with SATT Conectus for a Gene Therapy Candidate for the Treatment of the Fragile X Syndrome 150 150 Lysogene

Strengthening of Lysogene’s pipeline with a new drug candidate for a pathology with high unmet…

Lysogene Reports its Cash Position as of 31 March 2021

Lysogene Reports its Cash Position as of 31 March 2021 150 150 Lysogene

Cash and cash equivalents of €20.0 million[1] as of 31 March 2021 Paris, France —…

Lysogene COVID-19 update

Get In Touch

Don’t hesitate to contact us if you need more help.